-
[Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling
09 May 2012 | | Contributor(s):: Elvira de Mejia
Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer...
-
[Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)
09 May 2012 | | Contributor(s):: Jennifer Stone
Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...
-
[Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents
09 May 2012 | | Contributor(s):: Richard B. Jones
A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer...
-
[Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations
09 May 2012 | | Contributor(s):: Jack Pu Hou
One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...
-
[Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer
09 May 2012 | | Contributor(s):: Mary Jo Laws
We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian tumors...
-
[Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research
09 May 2012 | | Contributor(s):: John F. McDonald
The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...
-
[Illinois] Cancer Community Symposium 2012: Closing Address and Awards
09 May 2012 | | Contributor(s):: Rohit Bhargava
Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...
-
KIST/PU Advances in detection systems for biology: Classifying signals from fluorescence and scatter
08 Dec 2011 | | Contributor(s):: J. Paul Robinson
Biology-driven advances in photonic detection systems have been dramatic in the last several years. Three specific aspects are of particular interest: molecular detection, cellular detection, and whole-organ or small-animal imaging. Each area of study requires specific probes, detectors, and...
-
KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor
07 Dec 2011 | | Contributor(s):: Youngro Byun
Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application due to its unsatisfactory therapeutic effects and a strong anticoagulant activity, which induces...
-
KIST/PU 6th Annual Symposium: High Impact Research to Society
07 Dec 2011 |
In 2006, the South Korean Ministry of Science and Technology selected the KIST and Purdue team project from 20 international research proposals submitted to examine how to learn more about the molecular makeup of diseases.
-
KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?
06 Dec 2011 | | Contributor(s):: J. Paul Robinson
Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions
-
KIST/PU Designing a Research Program Around Unmet Clinical Needs
06 Dec 2011 | | Contributor(s):: Alyssa Panitch
-
KIST/PU Theragnosis – A New Paradigm of Personalized Medicine
06 Dec 2011 | | Contributor(s):: Ick Chan Kwon
Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given...
-
Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements
05 Dec 2011 | | Contributor(s):: Elise Corbin
The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms through which a cell's physical properties influence cell growth, cell differentiation, cell cycle...
-
Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy
05 Dec 2011 | | Contributor(s):: Li Tang
Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer treatment. The size of these drug delivery vehicles has been strongly correlated with their in...
-
BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention
02 Dec 2011 | | Contributor(s):: Deborah W Knapp
Guest lecturer: Deborah Knapp.
-
Illinois 2011 NanoBiophotonics Summer School: Poster Day: Hadiyah Nicole Green
29 Nov 2011 | | Contributor(s):: Hadiyah Nicole Green, Nadia Jassim
Cancer laser treatment using gold nanorods.
-
BME 695L Lecture 13: Designing Nanomedical Systems (NMS) for In-vivo Use
22 Nov 2011 | | Contributor(s):: James Leary
See references below for related reading.13.1 Bringing in-vivo considerations into NMS design13.1.1 the in-vitro to ex-vivo to in-vivo paradigm 13.1.1.1 In-vitro - importance of choosing...
-
BME 695L Lecture 14: Designing and Testing Integrated Nanomedical Systems
22 Nov 2011 | | Contributor(s):: James Leary
See references below for related reading.14.1 Introduction to integrated designs14.1.1 “Total design” but there is some order in the design process14.1.2 A brief outline of the total design...
-
Illinois BioNanotechnology and Nanomedicine: Applications in Cancer and Mechanobiology Lecture 19: How can you tell if a cell is cancerous?
14 Nov 2011 | | Contributor(s):: Catherine J. Murphy
Lecture by Catherine Murphy.